If brilacidin can get severely ill patients dc’d straight from the icu then look out! That would be a minor miracle. When they say severe are they talking mostly about ventilated patients and patients heading towards ventilation? Because once they get to that point isn’t a lot of the damage from cytokine storm irreversible? I don’t think anything can help at that point. We need to catch it before then, and I guess that’s where the moderate patients come in. But my concern is that brilacidins moa is geared more towards mildly and moderately symptomatic patients, controlling the virus before damage is done. I guess it could help with secondary bacterial infections in severe patients, but once lung damage reaches a certain point, there’s no recovery, no mater how well a drug controls the virus. We could have a near perfect antiviral, but if we’re dosing patients at the wrong stage, we may not know it. I was hoping they could somehow include mildly symptomatic patients to see if it could knock out symptoms quickly, kind of like tamiflu is supposed to. I don’t know much about clinical trials though. I guess mild patients aren’t in the hospital and probably wouldn’t want to take an investigational drug anyway.

I guess my point is I hope they include a lot of moderate patients and not mostly severe patients